Reduction in Physician Reimbursement and Use of Hormone Therapy in Prostate Cancer
Reads0
Chats0
TLDR
The 2003 Medicare Modernization Act reduced reimbursements for AST by 64% between 2004 and 2005, but the effect of this large reduction on use of AST in prostate cancer is unknown.Abstract:
Background
Use of androgen suppression therapy (AST) in prostate cancer increased more than threefold from 1991 to 1999. The 2003 Medicare Modernization Act reduced reimbursements for AST by 64% between 2004 and 2005, but the effect of this large reduction on use of AST is unknown.read more
Citations
More filters
Journal ArticleDOI
Comparison of SEER Treatment Data With Medicare Claims
Anne-Michelle Noone,Jennifer L. Lund,Angela B. Mariotto,Kathleen A. Cronin,Timothy S. McNeel,Dennis Deapen,Joan L. Warren +6 more
TL;DR: SEER data should not generally be used for comparisons of treated and untreated individuals or to estimate the proportion of treated individuals in the population, andAugmenting SEER data with other data sources will provide the most accurate treatment information.
Journal ArticleDOI
Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer
Journal ArticleDOI
Use of the Medicare database in epidemiologic and health services research: a valuable source of real-world evidence on the older and disabled populations in the US.
Katherine E Mues,Alexander Liede,Jiannong Liu,James B. Wetmore,Rebecca Zaha,Brian D. Bradbury,Allan J. Collins,David T. Gilbertson +7 more
TL;DR: A summary of Medicare data is provided, including the types of data that are captured, and how they may be used in epidemiologic and health outcomes research, to highlight strengths, limitations, and key considerations when designing a study using Medicare data.
Journal ArticleDOI
Pharmaceutical policies: effects of financial incentives for prescribers
TL;DR: The effects of pharmaceutical policies using financial incentives to influence prescribers' practices on drug use, healthcare utilisation, health outcomes and costs are determined and pay for performance policies are evaluated.
References
More filters
Journal ArticleDOI
Changes in body composition during androgen deprivation therapy for prostate cancer.
Matthew R. Smith,Joel S. Finkelstein,Francis J. McGovern,Anthony L. Zietman,Mary Anne Fallon,David A. Schoenfeld,Philip W. Kantoff +6 more
TL;DR: GnRH agonists increase weight and percentage fat body mass and decrease percentage lean body mass, fat distribution, and muscle size in men with nonmetastatic prostate cancer.
Journal ArticleDOI
Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31.
Miljenko V. Pilepich,Richard J. Caplan,R. W. Byhardt,Colleen A. Lawton,M J Gallagher,John B. Mesic,Gerald E. Hanks,Christopher T. Coughlin,Arthur T. Porter,William U. Shipley,D. Grignon +10 more
TL;DR: Application of androgen suppression as an adjuvant to definitive radiotherapy has been associated with a highly significant improvement in local control and freedom from disease progression.
Journal ArticleDOI
Metabolic Syndrome in Men With Prostate Cancer Undergoing Long-Term Androgen-Deprivation Therapy
Milena Braga-Basaria,Adrian S. Dobs,Denis C. Muller,Michael A. Carducci,Majnu John,Josephine Egan,Shehzad Basaria +6 more
TL;DR: Data suggest that metabolic syndrome was present in more than 50% of the men undergoing long-term ADT, predisposing them to higher cardiovascular risk.
Journal ArticleDOI
Utility of the SEER-Medicare data to identify chemotherapy use.
Joan L. Warren,Linda C. Harlan,Angela Fahey,Beth A Virnig,Jean L. Freeman,Carrie N. Klabunde,Gregory S. Cooper,Kevin B. Knopf +7 more
TL;DR: The utility of Medicare data to measure treatment with specific agents varies by cancer type and specific agent, and high level of agreement between Medicare claims and POC data regarding whether or not the patient had received chemotherapy is found.